8-K: STERIS plc Reports Strong Q3 Results, Raises Fiscal 2024 Outlook

STERIS plc announced a 15% increase in third-quarter revenue and updated its fiscal 2024 outlook, driven by strong performance in its Healthcare segment.

Summary

• STERIS plc reported a 15% increase in revenue to $1.40 billion for the third quarter of fiscal year 2024, compared to $1.22 billion in the same period last year.
• Constant currency organic revenue grew by 10% in the third quarter.
• Diluted earnings per share increased to $1.42, while adjusted earnings per share rose to $2.22.
• The Healthcare segment saw a 19% revenue increase, reaching $916.2 million, with strong growth in consumables, capital equipment, and services.
• Applied Sterilization Technologies (AST) revenue increased by 6% to $234.9 million, while Life Sciences revenue grew by 21% to $146.6 million.
• Dental segment revenue declined by 5% to $97.9 million.
• Net cash provided by operations for the first nine months of fiscal 2024 was $718.5 million, compared to $541.1 million in the same period last year.
• Free cash flow for the first nine months of fiscal 2024 was $457.0 million, compared to $262.8 million in the prior year period.
• The company has increased its fiscal 2024 revenue growth outlook to 10-11% as reported and 7-8% on a constant currency organic basis.
• Adjusted earnings per diluted share are now expected to be in the range of $8.60 to $8.70 for fiscal 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased earnings, and an improved outlook. While there are some challenges in the Dental segment and a slight reduction in adjusted EPS guidance, the overall tone is optimistic and indicates a healthy business performance.

Positives

• The company experienced strong revenue growth across multiple segments, particularly in Healthcare and Life Sciences.
• The increase in free cash flow indicates improved financial health and flexibility.
• The company's updated fiscal 2024 outlook reflects confidence in continued performance.
• The Healthcare segment saw significant growth in all revenue categories: consumables, capital equipment, and services.
• The Life Sciences segment experienced substantial growth in capital equipment revenue.
• The company is successfully reducing backlog levels due to easing supply chain constraints.

Negatives

• The Dental segment experienced a 5% decline in revenue.
• Underlying service revenue growth in the AST segment continues to be impacted by Medtech customer inventory management and reduced demand from bioprocessing customers.
• The adjusted earnings per share outlook was slightly reduced due to a shift in operating income mix from AST to Healthcare.

Risks

• The company faces potential risks from supply chain disruptions, changes in market conditions, and competitive factors.
• There are risks associated with the integration of acquired businesses, including potential liabilities and integration costs.
• Changes in tax laws and interpretations could increase the company's consolidated tax liabilities.
• The company is exposed to international unrest, economic downturns, and currency fluctuations.
• There is a risk of reduced demand for the company's products and services.
• The company faces potential delays in orders, manufacturing, or shipment of products due to supply chain issues.

Future Outlook

The company expects fiscal 2024 revenue to increase by 10-11% as reported and 7-8% on a constant currency organic basis. Adjusted earnings per diluted share are anticipated to be in the range of $8.60 to $8.70.

Management Comments

• The continued momentum in our Healthcare segment reflects solid procedure volume growth in the United States and the easing of supply chain constraints which allowed us to continue to reduce backlog levels.
• In addition, revenue within our Life Sciences segment improved during the quarter.
• Our revenue outlook for fiscal 2024 has increased as we continue to experience outperformance within the Healthcare segment, offsetting macro challenges impacting demand in our other segments.

Industry Context

The strong performance in the Healthcare segment aligns with the broader trend of increased healthcare spending and procedure volumes. The Life Sciences growth reflects the ongoing demand for bioprocessing and research equipment. The decline in the Dental segment may indicate a broader slowdown in that market.

Comparison to Industry Standards

• STERIS's 15% revenue growth in Q3 is strong compared to some of its peers in the medical device and sterilization industry, such as Getinge and Cantel Medical (now part of STERIS), which have seen more modest growth in recent quarters.
• The 10% constant currency organic growth is also a positive indicator, suggesting that the company's growth is not solely driven by acquisitions.
• The free cash flow of $457 million for the first nine months is a significant improvement, indicating strong operational efficiency and cash management compared to previous periods and some competitors.
• The Healthcare segment's 19% growth is particularly noteworthy, outperforming many competitors in the medical device space.
• However, the Dental segment's 5% decline is a concern and may indicate a need for strategic adjustments in that area, as other dental companies have shown mixed results.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased outlook.
• Employees may benefit from the company's improved performance and growth prospects.
• Customers will continue to receive products and services from a financially stable company.
• Suppliers may see increased demand for their products and services due to STERIS's growth.

Next Steps

• STERIS management will host a conference call on February 8, 2024, to discuss the results.
• The company will continue to focus on driving growth in its Healthcare and Life Sciences segments.
• The company will monitor and address the challenges in the Dental segment.

Key Dates

Keywords

STERIS, Healthcare, Life Sciences, Revenue, Earnings, Financial Results, Medical Devices, Sterilization, Operating Income, Free Cash Flow